|
Variables
|
MSD (n = 42)
|
AD (n = 69)
|
χ2
|
P-value
|
|---|
|
Acute GVHD (n, %)
|
0.435
|
0.509
|
|
Yes
|
15 (35.7)
|
29 (42.0)
|
|
No
|
27 (64.3)
|
40 (58.0)
|
|
Grade II-IV aGVHD (n, %)
|
3.788
|
0.052
|
|
Yes
|
2 (4.8)
|
12 (17.4)
|
|
No
|
40 (95.2)
|
57 (82.6)
|
|
Chronic GVHD (n, %)
|
0.046
|
0.83
|
|
Yes
|
9 (21.4)
|
16 (23.2)
|
|
No
|
33 (78.6)
|
53 (76.8)
|
|
IPFD (n, %)
|
0.274
|
0.601
|
|
Yes
|
12 (28.6)
|
23 (33.3)
|
|
No
|
30 (71.4)
|
46 (66.7)
|
|
Hemorrhagic cystitis (n, %)
|
3.690
|
0.055
|
|
Yes
|
8 (19.0)
|
25 (36.2)
|
|
No
|
34 (81.0)
|
44 (63.8)
|
|
EBV infection (n, %)
|
17.674
|
< 0.001
|
|
Yes
|
1 (2.4)
|
26 (37.7)
|
|
No
|
41 (97.6)
|
43 (62.3)
|
|
CMV infection (n, %)
|
13.100
|
< 0.001
|
|
Yes
|
9 (21.4)
|
39 (56.5)
|
|
No
|
33 (78.6)
|
30 (43.5)
|
|
Relapse (n, %)
|
5.056
|
0.025
|
|
Yes
|
19 (45.2)
|
17 (24.6)
|
|
No
|
23 (54.8)
|
52 (75.4)
|
|
Death (n, %)
|
4.197
|
0.041
|
|
Yes
|
16 (38.1)
|
14 (20.3)
|
|
No
|
26 (61.9)
|
55 (79.7)
|
|
Non-relapse mortality (n, %)
|
4.051
|
0.044
|
|
Yes
|
1 (6.3)*
|
5 (35.7)*
|
|
No
|
15 (93.4)*
|
9 (64.3)*
|
- GVHD graft-versus-host disease, IPFD Invasive pulmonary fungal disease, EBV Epstein-Barr virus, CMV Cytomegalovirus; *Non-relapse mortality and relapse mortality as a percentage of total deaths
